All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the long-term outcomes for patients treated with crenolanib combination therapy.
What are the long-term outcomes for patients treated with cenolanib combination therapy?
Wang presents the long-term outcomes for patients with newly diagnosed FLT3 mutant disease receiving crenolanib (a FLT3 tyrosine kinase inhibitor) and intensive chemotherapy. Wang outlines the study design, efficacy, and safety results of the long-term, multicenter study. Finally, Wang highlights the ongoing phase III trial, which could yield promising results for younger patients treated with potent second-generation FLT3 inhibitors.
Subscribe to get the best content related to AML delivered to your inbox